Plasma glutathione peroxidase (GPx-3) is a selenocysteine-containing protein with antioxidant properties. GPx-3 deficiency has been associated with cardiovascular disease and stroke. The regulation of GPx-3 expression, however, remains largely uncharacterized, and we studied its transcriptional and translational determinants in a cultured cell system. In transient transfections of a renal cell line (Caki-2), the published sequence cloned upstream of a luciferase reporter gene produced minimal activity (relative luminescence [RL]: 0.6 ± 0.4). Rapid amplification of cDNA ends was used to identify a novel transcription start site that is located 233 bp downstream (3') of the published site and that produced an over 25-fold increase in transcriptional activity (RL: 16.8 ± 1.9; p<0.0001). Analysis of the novel GPx-3 promoter identified Sp-1 and hypoxia-inducible factor 1 (HIF-1) binding sites, as well as the redoxsensitive metal response element and antioxidant response element. Hypoxia was identified as a strong transcriptional regulator of GPx-3 expression, in part through the presence of the HIF-1 binding site, leading to an almost three-fold increase in expression levels after 24 hr compared to normoxic conditions (normalized RL: 3.49 ± 0.30 vs. 1.18 ± 0.14; p<0.001). We also investigated the role of the translational cofactors tRNA sec (tRNA), SECIS-binding protein 2 (SBP2), and selenophosphate synthetase D (SelD) in GPx-3 protein expression. tRNA sec and
Introduction
Plasma glutathione peroxidase (GPx-3) is one of five known glutathione peroxidases (1) and one of at least 25 identified selenocysteine-containing enzymes in mammals (2) . GPx-3 is unique among the members of the GPx family as the only extracellular isoform (3) . It is a glycosylated tetramer of 23 kD subunits that catalyzes the reduction of hydrogen peroxide and lipid peroxides at the expense of glutathione, and is a major scavenger of reactive oxygen species (ROS) produced during normal metabolism or after oxidative insult (4, 5) . The GPx-3 gene contains 5 exons that span approximately 10 kB in the q32 region of chromosome 5 (6) . While mRNA for GPx-3 has been found in most cell types studied (7) (8) (9) , the mature protein is basolaterally secreted from renal proximal tubular cells and parietal epithelial cells of Bowman's capsule (10, 11) . This localization was determined by in situ analysis of mouse kidney, and supported by the clinical observation that anephric individuals (10) and patients with renal dysfuntion (12) have significantly lower levels of GPx-3 activity in plasma than healthy subjects.
In addition to plasma, GPx-3 activity has been detected in lung lavage fluid (9) and breast milk (13) .
Previous studies in our laboratory have shown an association between decreased levels of GPx-3 activity in plasma and familial childhood stroke (14, 15) . Western blot analyses showed that this reduction in GPx-3 activity correlated with lower protein expression (unpublished data); however, the mechanism for this downregulation is unknown. The regulation of GPx-3 transcription and translation remains largely uncharacterized (16) (17) (18) (19) . A transcription start site (tsp) located 298 bp upstream of the translation start site has been proposed (6) , yet no basal activity has been detected with promoter constructs based upon this tsp (20) despite synthesis of mRNA in the basal state (21) . Only one study to date has reported regulation of the promoter of by guest on http://www.jbc.org/ Downloaded from the GPx-3 gene: Comhair and colleagues showed that transfection of a reporter gene construct containing 3.2 kb of the GPx-3 promoter into epithelial lung cells (BET1A cells) resulted in increased expression levels in response to treatment with a combination of pyrogallol and reduced glutathione (GSH) (20) . In addition, GPx-3 synthesis has been shown to be regulated in part by selenium levels (22) , but whether this regulation occurs at the transcriptional or translational level remains to be determined. Thus, we sought to identify the determinants of GPx-3 expression by studying its transcriptional and translational regulation in vitro.
Experimental Procedures

Cell culture
Media and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY).
Complete media refers to media with FBS as described for each cell type. Except for humanastrocytoma derived cells (HTB13), cells were maintained at 37 o C in 95% O 2 and 5% CO 2 .
Caki-2 cells purchased from American Type Culture Collection (ATCC, Manassas, VA) were grown in McCoy's 5A media supplemented with L-glutamine, 25 mM HEPES, and 10% FBS.
Human embryonic kidney (HEK293) cells were grown in Dulbecco's Modified Essential Media supplemented with 4.5 g/L glucose, L-glutamine, pyridoxine HCl, 110 mg/L sodium pyruvate, and 10% FBS. Human vascular endothelial cells (HUVEC) purchased from Clonetics were maintained in EBM-2 media (Clonetics, San Diego, CA), which consists of EBM endothelial cell basal medium supplemented with the EBM-bullet kit (final concentrations: 2% FBS, 10 ng/ml human recombinant epidermal growth factor, 1 µg/ml hydrocortisone, 50 µg/ml gentamicin, 50 ng/ml amphotericin B, and 12 µg/ml bovine brain extract; Clonetics Mar, CA) and exposed to 95% N 2 and 5% CO 2 for 30 minutes; the chamber was then sealed and returned to the incubator. Experiments with hypoxic cells were performed inside an inflatable glove bag purged with 95% N 2 and 5% CO 2 to maintain hypoxic conditions.
5' Rapid Amplification of cDNA Ends (RACE)
Human kidney RACE-ready cDNA (Ambion, Austin, TX) was amplified using three 
GPx-3 Reporter Constructs
A reporter construct containing approximately 1300 bp of the GPx-3 5' region (positions -1237 to +35) was generated by PCR amplification of genomic DNA using the sense primer, 5'-ATATGGTACCGTCAGAGAGATTTGAGACTGATTCC-3' and the antisense primer, 5'-CCTAAAGCTTTGAGCCGCTGCCTGATCCC-3', which contain a KpnI site and a HindIII site, respectively (underlined). This construct was designated the full-length construct (construct A). Four deletion constructs (constructs B -E) were generated with the same antisense primer as above and the sense primers shown in 
DNA sequencing
All constructs and RACE products were sequenced with a fluorescence dideoxytermination method using an automated sequencer (Big Dyes, Model ABI 377-96). DNA sequencing was performed by the Molecular Genetics Core Laboratory at Boston University School of Medicine.
Transient Transfections of GPx-3 Reporter Constructs
Four different cell types were transfected with the GPx-3 luciferase constructs: Caki-2, HUVEC, HTB13, and HEK293 cells. The transfection methods were optimized for each cell type. Caki-2 cells were seeded in 12-well plates and the remaining cell types in 24-well plates, and allowed to reach 70-90% confluence. For Caki-2 cells, 2 µg luciferase construct, 20 ng CMV renilla (pRL-CMV, Promega) construct, and 3 µl Superfect (Qiagen) were combined with serum-free media for a total volume of 75 µl. This mixture was incubated for 10 min before adding 400 µl of pre-warmed, complete media. Cells were washed twice with serum-free media, and the transfection mixture was added to the cells for 2 hr at 37 o C. The transfection mixture was removed by washing twice with phosphate-buffered saline (PBS) and replaced with complete media until cells were either treated with conditioned media or harvested.
For HUVEC, 0.5 µg luciferase construct, 0.133 µg CMV renilla construct, and 2.5 µl Superfect were combined with serum-free media for a total volume of 37.5 µl and incubated for The transfection mixture was removed and replaced with complete media for 22 hr.
Luciferase Assays
Cells were harvested by washing twice with PBS without calcium (Gibco) and then rocked in the presence of 100 µl (for 24-well plates) or 250 µl (for 12-well plates) passive lysis buffer (Promega) for 1 -2 hr. All luciferase measurements were made using a Turner TD-20e luminometer according to the manufacturer's instructions (Dual-Reporter Assay, Promega).
Firefly luciferase luminescence measurements were normalized to renilla luciferase luminescence measurements prior to any additional comparison or analysis.
Generation of GPx-3 cDNA
GPx-3 cDNA was generated by reverse transcriptase PCR (RT-PCR) on RNA purified 
GPx-3 Protein Expression
HEK293 cells were plated in either 100-mm dishes or 6-well plates and grown until 60-70% confluent prior to treatment. Experimental conditions are described for 100-mm dishes.
Selenium incorporation was performed after overnight recovery from transfection, using published procedures (23) . Transfection media included 75 µl lipofectAMINE (Gibco) with the 
Results
5' Rapid Amplification of cDNA Ends
Previously published chromosomal alignment and primer extension studies have suggested that the tsp of the GPx-3 gene is located 298 bp upstream of its translational start site (6) . Preliminary work with this start site showed little promoter activity in a luciferase-based reporter construct in Caki-2 cells, a cell-line derived from renal proximal tubules, and prompted the use of a RACE procedure to identify potential alternative start sites in these cells. We used human kidney RACE-ready cDNA with an adapter sequence ligated to its 5'end. A sense primer specifically designed against the adapter sequence was used in combination with three different antisense primers specific to GPx-3: upstream of the published tsp, in exon 1 relative to the published tsp, and in exon 2. The only combination of primers that resulted in a reproducible RACE product was that with the antisense primer based in exon 2 ( Fig. 1) . Sequencing of this product confirmed that it aligned with the published GPx-3 cDNA sequence and showed that it contained 64 bp of 5' untranslated sequence. This result suggested the location of a novel tsp
Sequence Analysis
Three sequences for the GPx-3 promoter are available in Genbank: accession numbers D16360 (6), AF285633 (20) , and AY310878 (24). Our sequence (accession number AY552097)
is 100% homologous to that reported most recently by Rieder and colleagues (Genbank accession number AY310878) (24). We analyzed the sequence located between the published tsp and our newly identified, downstream tsp for conserved sequence motifs and potential 
Promoter Function
Caki-2 cells have previously been shown to express GPx-3 in quantities greater than cell lines from other source organs (21) . To test whether the newly identified promoter sequence could drive basal expression, luciferase constructs containing varying lengths of the GPx-3
promoter were transfected into Caki-2 cells. Experiments were run in triplicate and performed a minimum of three times. Expression levels measured after 24 hr as the ratio of firefly to renilla luciferase luminescence are shown in Figure 3 . All constructs that included the newly identified tsp (constructs A -E) resulted in approximately 25-fold higher activity compared with a construct based on the published tsp alone (construct F; p<0.0001). Expression levels were similar for constructs A -E, suggesting that elements critical for promoter function lie within the 180 bp immediately upstream of the newly proposed tsp.
To determine whether this new tsp functioned in other cell types, we transfected three additional cell types: HEK293 cells (another kidney-derived cell line), HUVEC (owing to their contact with plasma), and HTB13 cells (as selenoproteins are reported to be most stable in the brain) (18) . To account for differences in transfection efficiency among cell types, the average ratio of luciferase to renilla was normalized to the average ratio produced by the pGL3 enhancer vector. As observed in the Caki-2 cells, the constructs containing the new downstream start site produced activity that was significantly higher than that of the construct lacking the new start site. The relative level of expression of all GPx-3 constructs in Caki-2 cells, however, was approximately 10-fold higher than that in the other cell types (data not shown); for this reason, all subsequent experiments were performed in Caki-2 cells.
Treatment with Oxidants
Comhair and colleagues showed an increase in GPx-3 promoter activity and in GPx-3 mRNA expression in BET1A cells (a human bronchial epithelial cell line that expresses GPx-3)
in response to the combination of 100 µM of the superoxide generator pyrogallol and 10 mM GSH (20) . Aside from this study, no other work has provided evidence for transcriptional regulation of the GPx-3 gene. There is evidence, however, that GPx-1, the cellular isoform of . In addition, we were unable to reproduce the significant stimulation of promoter activity with GSH and pyrogallol described by Comhair and colleagues using this new promoter in Caki-2 cells (data not shown).
Modulation by Hypoxia
As hypoxia has been shown to induce antioxidant enzyme expression and the proposed, new promoter sequence contains an HIF-1 binding site, we exposed Caki-2 cells transfected with the full-length promoter construct A to hypoxic conditions for 6 hr intervals up to 24 hr. Values were normalized to the expression levels of the full length construct A in normoxia at 6 hr. The transcriptional activity of the GPx-3 construct in normoxia remained relatively stable during the 24 hr period. In contrast, a progressive increase of GPx-3 transcriptional activity was observed under hypoxic conditions; for each timepoint, the GPx-3 construct maintained in hypoxia showed higher expression than its normoxic counterpart, with a maximal, 2.9-fold increase reached at 24 hr (normalized RL: 3.49 ± 0.30 vs. 1.18 ± 0.14, p<0.001) (Fig. 4A ). This induction of GPx-3 expression by hypoxia was consistent for all constructs with the exception of construct E (normalized RL: 2.03 ± 0.11), which lacked the HIF-1 response element (Fig. 4B) .
In an attempt to modulate the effects of hypoxia on GPx-3 gene expression, we treated hypoxic cells transfected with the full-length construct A with the nitric oxide donors, S-nitrosoglutathione (SNO-Glu) and diethylene triamine nitric oxide (DETA-NO), as well as with the thiol N-acetylcysteine (NAC) and the thiol precursor oxo-thiazolidine carboxylic acid (OTC); these latter two species increase intracellular levels of reduced glutathione and, therefore, have antioxidant properties. All treatments were performed for 2 hr after the cells had been maintained in hypoxia for 22 hr. Cells treated with either of the NO donors (normalized RL after treatment with 0.5 mM SNO-Glu: 2.47 ± 0.23; 5 mM DETA-NO: 2.66 ± 0.15) showed some reduction in transcriptional activity compared to untreated cells (normalized RL: 3.03 ± 0.37), yet this effect was not significant. In contrast, treatments with 20mM NAC (normalized RL:
1.51 ± 0.48) or 1 mM OTC (normalized RL: 1.44 ± 0.03) significantly reverted the transcriptional activation induced by hypoxia, reducing the expression levels almost to that of the normoxic construct (Fig. 5) . Treatment of transfected cells maintained in normoxia with these redox-active substances did not significantly influence translational activity (data not shown). These findings indicate that cellular redox status modulates the response of the GPx-3
promoter to hypoxia.
Overexpression of GPx-3
To determine the effects of translational cofactors on GPx-3 expression, we used [ 75 Se] to radiolabel newly synthesized selenocysteine proteins. This assay detected only recombinant GPx-3 in the media. Transfection of the renal cell line HEK293 with cDNA for GPx-3 and the translational cofactors tRNA sec and SelD resulted in clearly detectable protein (Fig. 6 , lanes 1 + 2) while no band was detected when only these cofactors were transfected without GPx-3 cDNA (Fig. 6, lanes 3 + 4) . It has previously been shown that overexpression of the known translational cofactors can enhance expression of (other) selenoproteins (23, 26, 27 (Fig. 7) . In the presence of the tRNA sec cDNA (Fig. 7A) or the SelD cDNA (Fig. 7B) , a statistically significant increase in expression of GPx-3 protein is apparent. In the presence of SBP2 (Fig. 7C) , a trend towards increased GPx-3 protein expression is observed.
These results show dependence of GPx-3 protein expression on translational cofactors unique to selenocysteine-containing proteins.
Discussion
The regulation of expression of the human GPx-3 gene is a complex process, and involves transcriptional and translational events that are incompletely understood. Although the kidney is the primary source of GPx-3, most regulation studies have focused on GPx-3 expression in the lung, with inconsistent results. Pulmonary epithelial cells exposed to hyperoxia as well as lung lavage fluid from patients exposed to ozone both have shown a decrease in GPx-3 activity compared with controls (28); in contrast, an increase in GPx-3 activity in lavage fluid was observed in mice exposed to hyperoxia (29) . Another study showed no change in GPx-3 mRNA expressed in airway epithelium and alveolar macrophages of patients given 12 hr of 100% oxygen (30) . These same investigators reported an induction of GPx-3 mRNA in response to cigarette smoke, and in a later study found that patients with asthma have higher levels of GPx-3 mRNA in their airway epithelium than do healthy controls (20) . The recently been reported to be regulated by oxygen tension, but through the presence of two oxygen responsive elements that, in contrast to HIF-1, activate transcription in response to increasing O 2 levels (34). The strong increase in expression of all GPx-3 constructs during hypoxia with the exception of the construct lacking the HIF-1 binding site supports the importance of this transcription factor in regulating GPx-3 levels. Expression levels were nevertheless increased even by this construct, which is most likely due to the presence of the other redox-sensitive elements, the ARE and MRE sites.
Hypoxia leads to the formation of ROS, mainly generated by mitochondria (35) (36) (37) , and there is strong evidence that these ROS play a central role in promoting ischemic injury in vitro and in vivo (38) . Thus, the susceptibility to these toxic compounds depends in part on the ability to upregulate ROS scavenging enzymes, such as GPx-3. Oxidative stress and/or variations in the intracellular redox state are well established modulators of the transcription of several genes (39) . Indeed, our results support that the upregulation of GPx-3 in the setting of hypoxia is, at least in part, redox-mediated, as the effect was modulated by treatment with thiols.
The association between decreased GPx-3 activity, arterial thrombosis, and the clinical manifestations of ischemic stroke (14) and coronary artery disease (40) (41) (42) , indicate that the normal function of this enzyme is important for vascular homeostasis. Nevertheless, some controversy has surrounded the role of plasma GPx-3 as an antioxidant enzyme in plasma, owing to the relatively low plasma concentration of GSH. Thioredoxin and glutaredoxin have been shown to function effectively as electron donors for GPx-3 in in vitro assays (43) at concentrations well below their normal plasma levels (nM range), and has been proposed to serve as reducing cofactors. In addition, a recent study has indicated that the apparent requirement for high concentrations of GSH was an artifact of assay conditions which resulted from the use of Tris buffer (44), thus suggesting that plasma GSH levels may after all be sufficient to act as a reductant for this enzyme.
Regulation of selenoproteins is unique in that their translation machinery enables an opal codon (UGA) to be read as coding for selenocysteine. Several translational cofactors have been described as necessary, but not alone sufficient, for synthesis of these proteins. SelD is responsible for the biosynthesis of selenocysteine from an L-serine bound to a special tRNA sec that can recognize the UGA codon (45) . Actual incorporation of selenocysteine into the nascent polypeptide involves the presence of a stem-loop structure formed by a selenocysteine insertion sequence (SECIS) in the 3' untranslated region of the mRNA and SBP2, a SECIS-binding protein, which recruits other factors necessary for incorporation (26) . The fact that translation of these proteins requires a complex of translational cofactor proteins inherently leads to multiple potential levels of regulation: transcriptional, post-transcriptional, and translational. For example, work with cellular glutathione peroxidase (GPx-1) has shown that its mRNA is subject to regulation by selenium at the level of degradation (46) . Owing to the complexity of translation, it is possible that significant regulation occurs post-transcriptionally; experiments are currently underway to address this issue.
To examine potential regulation at the translational level, we have successfully overexpressed GPx-3 and present results showing regulation by these translational cofactors.
Overexpression of selenoproteins is difficult. Barkats and colleagues showed that overexpression of GPx-1 results in, at most, a two-fold increase in activity when being driven by a SV40 promoter in an adenoviral system (47). Brigelius-Flohe and colleagues transfected an endothelial cell-line with GPx-4 and SelD and observed no increase in activity; however, when SelD was transfected into cells that had been stably transfected with the GPx-4 cDNA, a fivefold increase in expression was detectable (27) . Another study provided evidence for a contribution of SBP2 to selective upregulation of constructs containing SECIS elements specific for GPx-4 and SelP (26) . Here we have presented data suggesting modulation of GPx-3 translation by SelD, tRNA sec , and SBP2.
In summary, we have identified a novel and functional transcription start site that results in significantly higher basal transcriptional activity in Caki-2 cells compared to the previously characterized promoter. Alternative transcription has recently also been described for another member of the glutathione peroxidase family: phospholipid GPx (48, 49) . For the first time, hypoxia has been identified as a strong transcriptional regulator of GPx-3 expression, likely through an HIF-1-dependent mechanism. In addition, we have successfully overexpressed GPx-expression. These data represent novel findings in this complex field of selenocysteinecontaining protein expression. 
Figure Legends
Figure 4:
Regulation of GPx-3 Expression by Hypoxia. A. Caki-2 cells transfected with the full length GPx-3 promoter construct were maintained in normoxia (gray bars) or exposed to 95% N 2 and 5% CO 2 for 6 hr intervals up to 24 hr (striped bars). Expression levels were measured as the ratio of firefly to renilla luciferase luminescence and normalized to the full length construct in normoxia at 6 hr. *p<0.01 and **p<0.001 compared to expression levels at the same timepoint in normoxia. B. Luciferase constructs containing varying lengths of the GPx-3 promoter (constructs A -E) were transfected into Caki-2 cells and maintained in hypoxia for 24 hs (striped bars). Expression levels were normalized to the full length construct A in normoxia at 24 hr (gray bar). All GPx-3 constructs showed a similar induction of expression under hypoxic conditions, with the exception of construct E. *p<0.01 when compared to construct A in hypoxia. All experiments were run in triplicate and performed a minimum of three times. The density of each band was measured and the relative intensity to no cofactor control was calculated. These values were then compared to GFP and are presented relative to the latter. 
